BBK Worldwide^® Blog

The clinical trial landscape saw a lot of changes in 2021, from decentralized clinical trial adoption to a greater emphasis on diversity and inclusion. But what’s in store for 2022? We asked our industry experts to weigh in with their predictions.

Earlier this week, Cellectar Biosciences, a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, announced its partnership with BBK to provide concierge services for patients participating in its clinical studies. The services are designed to improve patients' and their caregivers' access to high-quality care and innovative treatments for their cancer.

Earlier this week, BBK's Senior Director of Patient Engagement Services Mike Johnson spoke with Outsourcing-Pharma to discuss the RSG^® Arrive travel program and its recent milestone of 20,000 completed trips.

In this in-depth interview, Mike discusses what sets this program apart from others as he highlights the concierge specialists who are experienced in understanding all the ramifications of a request, as it relates not only to arranging a travel itinerary but also ensuring the itinerary supports patient health, safety, and compliance. In addition, Mike shares insight into the significance of the milestone for BBK as well as the industry at large. Click here to read the full article.

Getting Decentralized Right

What Matters to Patients

In Part 2 of our two-part interview with Phil Kelly, we delve further into the patient perspective on decentralized clinical trials. We ask Phil Kelly to share his thoughts on patient needs, tools, technologies, and the patient experience.

If you are conducting a decentralized clinical trial or planning for one, this is a must-see segment, with valuable insight to leverage for success.

Getting Decentralized Right

What Matters to Patients

We know the industry is ready to embrace decentralized clinical trials. But what about patients? What do they think about decentralized clinical trials? What elements are important to them? And what should sponsors consider when designing such trials?

To dig deep, we spoke one-on-one with Phil Kelly, a bladder cancer patient and advocate. He shares his experience and insight in Part 1 of this two-part series on the patient perspective.

New eBook Available for Download

As we continue to focus our attention on underserved populations, we've just released a content-rich eBook full of guidance that study sponsors can leverage to create a more diverse and inclusive clinical trial environment. It features a bonus section with excerpts from our recent Q&A with Michele Russell-Einhorn, chief compliance officer and institutional official at Advarra, that provide an IRB's perspective on improving diversity and inclusion in clinical trials.

Improving Diversity and Inclusion in Clinical Trials

One-on-One with Advarra

Get an IRB's perspective on improving diversity and inclusion in clinical trials by watching our interview with Michele Russell-Einhorn, Chief Compliance Officer and Institutional Official at Advarra.

BBK Worldwide Featured in Newly Published Innovations in Pharmaceutical Development™

Guide Provides In-Depth Profiles of World’s Most Disruptive Pharma Services Innovators

BBK Worldwide has been recognized as a top innovator in Innovations in Pharmaceutical Development™. This newly published guide highlights the companies and thought leaders at the forefront of innovation in the pharmaceutical development space. 

As part of our Crystal Ball series, we asked BBK Worldwide President Matt Kibby to share his predictions for 2021, which include engaging  underrepresented populations in clinical research.

Matt Kibby, Principal, President

Is there a particular trend that you expect to have a significant impact on the industry in the coming year?

With COVID-19 dominating the headlines for much of 2020, one might expect that a key development for clinical R&D in 2021 will be the continued integration and expansion of services that support the hybridization / decentralization of clinical trials. Keeping trial participants – who tend to be older and at greater risk for complications from COVID-19 – away from clinical trial sites not only reduces the risk of SARS-COV-2 infection, but also offers the possibility of enrichment of the clinical trial experience; reduces the overall visit and expense burden for patients; and, moreover, reduces the trial burden on clinical trial site healthcare professionals.

What do doctors and nurses think about solutions designed to make clinical trials easier to conduct? Are they helpful? Do they alleviate burdens? And which ones do they prefer?

In this special Pharma15 Live! segment, BBK Worldwide^® industry experts Matt Kibby and Aaron Fleishman discuss recent Study Voices survey results that shed light on this topic. They examine doctor and nurse perspectives on services designed to provide support in conducting clinical trials — including services for virtual, hybrid, and decentralized clinical trials.

“We were looking at whether or not doctors and nurses at sites that were conducting clinical trials would appreciate different types of services that assist with their ability to conduct them."

-Matt Kibby, Principal, President, BBK Worldwide